Abstract 153P
Background
The approval of several PD-1/L1 axis inhibitors has revolutionized cancer therapy and established a role for CD8+ T cells in tumor destruction. While anti-PD-1 therapy has demonstrated durable responses, only a subset of patients respond. To improve response rates, we developed a multispecific PD-1/CD73 targeting DFC. CD73 catalyzes the rate limiting step in production of immuno-suppressive adenosine, which inhibits immune cell activation through a mechanism distinct from PD-1. Herein, we describe a first-in-class dual targeting DFC, comprising a multivalent conjugate of a small molecule CD73 inhibitor to a proprietary human IgG1 Fc-fusion with a PD-1 inhibitor peptide. This dual-targeting DFC has potential for differentiation from approved PD-1/L1 inhibitors.
Methods
Binding of the dual targeting DFC to biotinylated hPD-1 was determined using a commercial kit and to human CD8+ T cells by flow cytometry. CD73 inhibition was determined in cell-free and cell-based assays. Efficacy was evaluated in transgenic mice expressing human PD-1/PD-L1 with MC-38 (hPD-L1) tumors (Genoway, France). Tumor volumes were recorded and statistical analysis was by t-test (Mann-Whitney) or two-way ANOVA.
Results
The dual targeting DFC demonstrated potent activity against both checkpoint targets: Binding to hPD-1 with an IC50 of < 1 nM and functional inhibition of CD73 with an EC50 of 9 nM. Efficacy was determined in a humanized mouse model against the colon cell line MC-38 (hPD-L1). The dual targeting DFC demonstrated a statistically significant reduction in tumor volume (∼55%) at a dose of 3 mg/kg (P<0.0001). Pembrolizumab biosimilar at 10 mg/kg did not result in a significant reduction in tumor volume.
Conclusions
This work describes a dual targeting DFC with potent activity against two validated immune checkpoint pathways. The in vitro activity translated to efficacy in a humanized mouse model at doses as low as 3 mg/kg. The relative contributions of each ligand to activity against different tumors is under investigation as Cidara’s first multispecific DFC advances through preclinical development.
Legal entity responsible for the study
Cidara Therapeutics.
Funding
Cidara Therapeutics.
Disclosure
J. Levin, S. Döhrmann, N. Dedeic, A. Almaguer, D. Zuill, E. Abelovski, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt, J.N. Cole, G. Hough, J.B. Locke, L.W. Tari: Financial Interests, Personal, Full or part-time Employment: Cidara Therapeutics.
Resources from the same session
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display